

| DATE | LECTURER | CONTACT | TITLE |
|-------------------------|--------------------------|---|---|
| January 24.01.2024 | Timothy Yap | The University of Texas M. D. Anderson Cancer Center, Houston, United States of America | Advances in DDR targeting: what can we expect in the next years |
| February 14.02.2024 | Fernanda Herrera | CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland | Use of new biomarkers for translational research |
| March 27.03.2024 | Christina Yap | ICR - The Institute of Cancer Research, Sutton, United Kingdom | Optimizing the designs of early clinical trials in oncology |
| April 17.04.2024 | Serena Nik-Zainal | University of Cambridge-Wellcome Trust Centre for Stem Cell Research, Cambridge, United Kingdom | Novel insights in mutational signatures |
| May 22.05.2024 | Fabrice Barlesi | Gustave Roussy - Cancer Campus, Villejuif, France | New Kras inhibitors beyond G12C |
| June 19.06.2024 | Eric Van Cutsem | UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium | New immunotherapies beyond checkpoint inhibitors |
| September 25.09.2024 | Andrew Davis | Faculty of Medicine, University of Southampton | New drugs and new drugs combinations in relapsed/refractory lymphoma: areas of research in the CART era |
| October 23.10.2024 | Niels Van De Donk | UMC - University Medical Center Utrecht, Utrecht, Netherlands | Status of the art and future directions of CARTs and bispecific antibodies in multiple myeloma |
| November 20.11.2024 | TBD | | State of the art of cell-based therapies in solid tumors |